Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

ve, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure strains the heart, which can lead to limited physical activity and a reduced life expectancy. Over time, the heart weakens, can no longer pump blood efficiently and may eventually fail.

About APD811APD811, an orally bioavailable agonist of the prostacyclin receptor, is an investigational drug candidate discovered by Arena and intended for the treatment of PAH. Prostacyclin receptor agonists slow disease progression and improve exercise tolerance in PAH patients and are among the treatments administered as standard of care for advanced PAH. Currently available prostacyclin receptor agonists belong to the prostanoid class of molecules, and these products need to be administered frequently or continuously through intravenous, subcutaneous or inhaled delivery methods. Arena believes that an orally bioavailable, non-prostanoid prostacyclin receptor agonist that provides clinical benefits similar to currently available prostacyclin receptor agonists has the potential to improve the standard of care for PAH.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate is intended for weight management.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerabili
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... YORK , May 5, 2015  IBM Watson ... is collaborating with more than a dozen leading cancer ... and personalize treatment options for their patients. The institutes ... capabilities to reduce from weeks to minutes the ability ... and gather relevant information from medical literature to personalize ...
(Date:5/5/2015)... EXTON, Pa. , May 5, 2015  The ... global leader in pharmacokinetic testing of drugs and safety ... Gum , Associate Director of Preclinical Studies, presented at ... in Vision and Ophthalmology (ARVO) in Denver, ... presentation was "Safety Assessment of a Novel, Cross-Linked, Bio-Absorbable ...
(Date:5/5/2015)... 2015  American Laboratory Trading, Inc. (ALT), the leading ... industry veteran Anggie Becorest as their new ... based out of the company,s San Diego ... the company,s west coast operations, diversifying the company,s offerings, ... has been the leader in the refurbished lab equipment ...
Breaking Medicine Technology:Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3ALT Names Anggie Becorest Senior Vice President of Business Development 2
... Mich. and TOULOUSE, France, May 15 ... company,developing HDL-related compounds for the treatment of ... has completed a Phase I,clinical trial for ... candidates.,CER-002 is a peroxisome proliferator-activated receptor (PPAR),delta-specific ...
... for an Antiplatelet Therapy that, Combined, with Aspirin, ... and Aspirin, According to ... Mass., May 15 Decision Resources, one of ... and,healthcare issues, finds that Daiichi Sankyo/Eli Lilly,s Effient ...
Cached Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3
(Date:5/5/2015)... New York, New York (PRWEB) May 05, ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on ... cardiovascular complications due to their use of ... forward in the federal multidistrict litigation underway ... Illinois. According to court documents dated May ...
(Date:5/5/2015)... Viverae®, a health management and engagement ... multinational developer, manufacturer and marketer of innovative, life-enhancing ... oncology and surgical specialty products, as the recipient ... Award recognizes outstanding achievement in the design and ... client base. , Viverae reviewed the employee wellness ...
(Date:5/5/2015)... Jacksonville, Fla. (PRWEB) May 05, 2015 ... from the Commission on Cancer (CoC) of the American ... a cancer program must meet more than 30 Commission ... years through a survey process, and maintain levels of ... , When patients choose to seek care locally ...
(Date:5/5/2015)... Patricia George knows all too well the debilitating effects ... specialist at the University of Pittsburgh Medical Center (UPMC), ... idea entered her mind for Team PHenomenal Hope. ... 2010 PHA International Conference,” George recalled. “The speakers – ... climb up Mt. Kilimanjaro and I remember thinking how ...
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
Breaking Medicine News(10 mins):Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2
... abstain from promiscuous sex on 1 December 2005, the World ... // and ignorance with regard to AIDS are contributing towards ... Stephen Lewis, has called upon the world’s rich nations to ... is continuing to take a heavy toll in the African ...
... DNA vaccine trials conducted against the AIDS/HIV virus. The ... completed among 40 HIV- negative // volunteers. ... of vaccine biology. It involves direct injection of one ... human body. These vaccines precipitate an immune response so ...
... Medical Center shows that patient trust over their doctors would ... // death were to be enforced in the near future. ... a telephonic survey conducted among a group of 1,117 adults ... attitudes about physician aid in dying. The participants were required ...
... University of Michigan researchers says that women are better at ... this conclusion after tracking 490 heart patients, who were treated ... pain. ,All these patients had enrolled in the ... about themselves plus gave the limit that their heart could ...
... the increase in the fees for lab tests and treatment ... that this was necessary to maintain the quality of the ... is taking place at the institution since 1995. The budget ... revenue generated by it is only between Rs.12 to Rs.25 ...
... Breast cancer is more likely to occur in the case ... do not smoke at all, or start smoking later in ... at Rochester have revealed this. Women who start smoking before ... breast cancer. ,In comparison, women who started smoking after ...
Cached Medicine News:Health News:DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope 2
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
Medicine Products: